A detailed history of Royal Bank Of Canada transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 65,886 shares of CRDF stock, worth $282,650. This represents 0.0% of its overall portfolio holdings.

Number of Shares
65,886
Previous 5,367 1127.61%
Holding current value
$282,650
Previous $14,000 1935.71%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$2.31 - $5.35 $139,798 - $323,776
60,519 Added 1127.61%
65,886 $285,000
Q3 2024

Nov 14, 2024

SELL
$2.05 - $2.77 $32,191 - $43,497
-15,703 Reduced 74.53%
5,367 $14,000
Q2 2024

Aug 14, 2024

BUY
$2.22 - $5.89 $13,475 - $35,752
6,070 Added 40.47%
21,070 $46,000
Q1 2024

Nov 05, 2024

SELL
$1.46 - $5.91 $8,862 - $35,873
-6,070 Reduced 28.81%
15,000 $80,000
Q1 2024

May 15, 2024

BUY
$1.46 - $5.91 $21,219 - $85,895
14,534 Added 3118.88%
15,000 $80,000
Q4 2023

Feb 14, 2024

BUY
$0.96 - $1.55 $167 - $269
174 Added 59.59%
466 $0
Q3 2023

Nov 14, 2023

SELL
$1.38 - $2.18 $26,229 - $41,435
-19,007 Reduced 98.49%
292 $0
Q2 2023

Aug 14, 2023

BUY
$1.37 - $1.95 $434 - $618
317 Added 1.67%
19,299 $28,000
Q1 2023

May 15, 2023

SELL
$1.45 - $2.09 $5,800 - $8,360
-4,000 Reduced 17.4%
18,982 $31,000
Q4 2022

Feb 14, 2023

SELL
$1.22 - $1.66 $4,716 - $6,417
-3,866 Reduced 14.4%
22,982 $32,000
Q3 2022

Nov 14, 2022

SELL
$1.54 - $3.21 $27 - $57
-18 Reduced 0.07%
26,848 $41,000
Q2 2022

Aug 15, 2022

SELL
$1.17 - $2.61 $7,571 - $16,889
-6,471 Reduced 19.41%
26,866 $60,000
Q1 2022

May 16, 2022

SELL
$2.11 - $7.25 $33,200 - $114,078
-15,735 Reduced 32.07%
33,337 $83,000
Q4 2021

Feb 14, 2022

BUY
$5.18 - $7.24 $85,159 - $119,025
16,440 Added 50.38%
49,072 $295,000
Q3 2021

Nov 15, 2021

BUY
$5.01 - $7.58 $94,974 - $143,694
18,957 Added 138.63%
32,632 $217,000
Q2 2021

Aug 16, 2021

BUY
$6.65 - $10.04 $90,938 - $137,297
13,675 New
13,675 $90,000

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $186M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.